Latest Insider Transactions at Cara Therapeutics, Inc. (CARA)
This section provides a real-time view of insider transactions for Cara Therapeutics, Inc. (CARA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cara Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cara Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 15
2022
|
Jeffrey L. Ives |
SELL
Open market or private sale
|
Direct |
3,600
-18.87%
|
$32,400
$9.05 P/Share
|
|
Jul 15
2022
|
Harrison M Bains Jr Director |
SELL
Open market or private sale
|
Direct |
7,200
-22.31%
|
$64,800
$9.05 P/Share
|
|
Jun 15
2022
|
Richard Makara VP, Head of Accting;Controller |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+35.57%
|
-
|
|
Jun 02
2022
|
Martin Vogelbaum |
BUY
Grant, award, or other acquisition
|
Direct |
35,628
+26.33%
|
-
|
|
Jun 02
2022
|
Harrison M Bains Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,876
+26.9%
|
-
|
|
Jun 02
2022
|
Jeffrey L. Ives |
BUY
Grant, award, or other acquisition
|
Direct |
11,876
+38.37%
|
-
|
|
Jun 02
2022
|
Susan Ph.D. Shiff |
BUY
Grant, award, or other acquisition
|
Direct |
11,876
+38.37%
|
-
|
|
Apr 04
2022
|
Christopher Posner PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
2,006
-0.99%
|
$24,072
$12.67 P/Share
|
|
Apr 01
2022
|
Frederique Ph.D. Menzaghi CHIEF SCIENTIFIC OFF,SVP-R&D |
SELL
Open market or private sale
|
Direct |
1,784
-1.04%
|
$19,624
$11.91 P/Share
|
|
Apr 01
2022
|
Joana Goncalves CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,642
-2.15%
|
$18,062
$11.91 P/Share
|
|
Apr 01
2022
|
Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. |
SELL
Open market or private sale
|
Direct |
1,642
-1.58%
|
$18,062
$11.91 P/Share
|
|
Mar 03
2022
|
Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. |
SELL
Open market or private sale
|
Direct |
1,787
-1.69%
|
$19,657
$11.38 P/Share
|
|
Mar 03
2022
|
Thomas Charles Reilly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,044
-5.13%
|
$22,484
$11.38 P/Share
|
|
Feb 28
2022
|
Thomas Charles Reilly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,333
+11.8%
|
$53,330
$10.29 P/Share
|
|
Feb 28
2022
|
Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. |
BUY
Grant, award, or other acquisition
|
Direct |
5,333
+4.8%
|
-
|
|
Feb 25
2022
|
Joana Goncalves CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,972
-2.51%
|
$19,720
$10.29 P/Share
|
|
Feb 25
2022
|
Joana Goncalves CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+20.3%
|
-
|
|
Feb 25
2022
|
Frederique Ph.D. Menzaghi CHIEF SCIENTIFIC OFF,SVP-R&D |
SELL
Open market or private sale
|
Direct |
2,114
-1.22%
|
$21,140
$10.29 P/Share
|
|
Feb 25
2022
|
Frederique Ph.D. Menzaghi CHIEF SCIENTIFIC OFF,SVP-R&D |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+10.33%
|
-
|
|
Feb 25
2022
|
Christopher Posner PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+16.11%
|
-
|
|
Feb 25
2022
|
Thomas Charles Reilly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+36.68%
|
-
|
|
Feb 25
2022
|
Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. |
SELL
Open market or private sale
|
Direct |
1,972
-1.93%
|
$19,720
$10.29 P/Share
|
|
Feb 25
2022
|
Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+16.34%
|
-
|
|
Dec 17
2021
|
Thomas Charles Reilly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,170
+43.48%
|
-
|
|
Dec 17
2021
|
Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. |
BUY
Grant, award, or other acquisition
|
Direct |
11,495
+12.24%
|
-
|
|
Dec 17
2021
|
Joana Goncalves CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,607
+17.73%
|
-
|
|
Dec 17
2021
|
Frederique Ph.D. Menzaghi CHIEF SCIENTIFIC OFF,SVP-R&D |
BUY
Grant, award, or other acquisition
|
Direct |
12,607
+7.58%
|
-
|
|
Nov 12
2021
|
Jeffrey L. Ives |
SELL
Open market or private sale
|
Direct |
8,180
-53.19%
|
$130,880
$16.04 P/Share
|
|
Nov 01
2021
|
Joana Goncalves CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-2.13%
|
$17,000
$17.15 P/Share
|
|
Oct 29
2021
|
Christopher Posner PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
147,941
+33.82%
|
-
|
|
Oct 27
2021
|
Joana Goncalves CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-2.09%
|
$15,000
$15.0 P/Share
|
|
Sep 07
2021
|
Derek T Chalmers President & CEO |
SELL
Open market or private sale
|
Direct |
20,000
-1.98%
|
$300,000
$15.47 P/Share
|
|
Aug 30
2021
|
Derek T Chalmers President & CEO |
SELL
Open market or private sale
|
Direct |
8,440
-0.83%
|
$118,160
$14.2 P/Share
|
|
Aug 30
2021
|
Joana Goncalves CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,110
-4.22%
|
$29,540
$14.2 P/Share
|
|
Aug 30
2021
|
Frederique Ph.D. Menzaghi CHIEF SCIENTIFIC OFF,SVP-R&D |
SELL
Open market or private sale
|
Direct |
3,847
-2.65%
|
$53,858
$14.2 P/Share
|
|
Aug 30
2021
|
Thomas Charles Reilly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,982
-37.16%
|
$27,748
$14.2 P/Share
|
|
Aug 30
2021
|
Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. |
SELL
Open market or private sale
|
Direct |
1,759
-2.42%
|
$24,626
$14.2 P/Share
|
|
Aug 24
2021
|
Derek T Chalmers President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
17,334
+1.67%
|
-
|
|
Aug 24
2021
|
Frederique Ph.D. Menzaghi CHIEF SCIENTIFIC OFF,SVP-R&D |
BUY
Grant, award, or other acquisition
|
Direct |
9,600
+6.21%
|
-
|
|
Aug 24
2021
|
Joana Goncalves CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+11.35%
|
-
|
|
Aug 24
2021
|
Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. |
BUY
Grant, award, or other acquisition
|
Direct |
5,334
+6.84%
|
-
|
|
Aug 24
2021
|
Thomas Charles Reilly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,334
+50.0%
|
-
|
|
Jun 07
2021
|
Jeffrey L. Ives |
SELL
Open market or private sale
|
Direct |
2,520
-14.08%
|
$32,760
$13.05 P/Share
|
|
Jun 07
2021
|
Christopher Posner PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
2,304
-12.52%
|
$29,952
$13.04 P/Share
|
|
Jun 07
2021
|
Martin Vogelbaum |
SELL
Open market or private sale
|
Direct |
8,640
-30.0%
|
$112,320
$13.05 P/Share
|
|
Jun 03
2021
|
Harrison M Bains Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,200
+26.09%
|
-
|
|
Jun 03
2021
|
Jeffrey L. Ives |
BUY
Grant, award, or other acquisition
|
Direct |
7,200
+28.69%
|
-
|
|
Jun 03
2021
|
Christopher Posner PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
7,200
+28.13%
|
-
|
|
Jun 03
2021
|
Susan Ph.D. Shiff |
BUY
Grant, award, or other acquisition
|
Direct |
7,200
+50.0%
|
-
|
|
Jun 03
2021
|
Martin Vogelbaum |
BUY
Grant, award, or other acquisition
|
Direct |
14,400
+33.33%
|
-
|